Centre Hospitalier Sud Francilien

The trials here

What the 59 trials at this site are about, from their registry records.

Conditions

• Type 1 diabetes13 trials
• Type 2 diabetes6 trials
• Multiple myeloma5 trials
• Chronic lymphocytic leukaemia4 trials
• Stroke4 trials
• Acute myeloid leukaemia3 trials
• Chronic kidney disease3 trials
• Obesity3 trials
• Asthma2 trials
• Chronic myeloid leukaemia2 trials
• Colorectal cancer2 trials
• Coronary artery disease2 trials
• and 19 more

Phase

• Phase 321 trials
• Phase 212 trials
• Phase 2/31 trial
• Phase 41 trial

Status

• Completed22 trials
• Active, not recruiting14 trials
• Recruiting11 trials
• Not yet recruiting10 trials
• Withdrawn2 trials

Lead sponsor

• Centre Hospitalier Sud Francilien13 trials
• Eli Lilly and Company5 trials
• Federation Francophone de Cancerologie Digestive4 trials
• Assistance Publique Hopitaux De Paris3 trials
• Intergroupe Francophone du Myelome3 trials
• and 24 more

Running trials

• Not yet recruiting

  Tumoral Versus Luminal Microbiome in Head and Neck Squamous Cell Carcinoma

  NCT07809100· Centre Hospitalier Sud Francilien· Source

  Contact: Renato TORRES, MD

• Not yet recruiting

  Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

  NCT07739459· Phase 2· The Lymphoma Academic Research Organisation· Source

• Not yet recruiting

  FILOCLL017 - NEVOTAL : Nemtabrutinib in addition to Venetoclax-Obinutuzumab in chronic lymphocytic leukemia (CLL) / small lymphocytic leukemia (SLL) patients with TP53 ALterations

  2026-525763-40-00· Phase 2· French Innovative Leukemia Organization (F.I.L.O.).· Source

• Not yet recruiting

  Evaluation of the Efficacy and Safety of Bimekizumab (BZK) or Adalimumab (ADA) in the Treatment of Anterior Chest Wall Pain Associated With Active Axial Spondyloarthritis Refractory to NSAIDs With Hypothesis of Superiority of Bimekizumab

  NCT07836283· Phase 3· University Hospital, Rouen· Source

• Not yet recruiting

  Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II Trial

  NCT07721363· Phase 2· Assistance Publique - Hôpitaux de Paris· Source

• Not yet recruiting

  Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL).

  NCT07624799· Phase 2· French Innovative Leukemia Organisation· Source

• Recruiting

  A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

  NCT07761117· Phase 3· AstraZeneca· Source

• Recruiting

  A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

  NCT07753993· Phase 3· AstraZeneca· Source

• Recruiting

  Cohort of Patients With Chronic Myelomonocytic Leukemia

  NCT07512882· Gustave Roussy, Cancer Campus, Grand Paris· Source

  Contact: Guillemette FOUQUET

• Recruiting

  Omnipod-5 A French Prospective Multicentric Study in Real World (Optimal-B)

  NCT07317102· Insulet Corporation· Source

  Contact: Catherine PETIT

• Recruiting

  Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer

  NCT07124858· Federation Francophone de Cancerologie Digestive· Source

  Contact: SAMY LOUAFI

• Not yet recruiting

  PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma

  NCT07128290· Phase 2· Federation Francophone de Cancerologie Digestive· Source

• Active, not recruiting

  French Prospective Multicentric Study in Real World

  NCT07039942· Insulet Corporation· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Intranasal Sufentanil for Analgesia of Severe Sickle Cell Vaso-occlusive Pain Crisis in the Pediatric Emergency Department

  2023-504847-15-00· Phase 3· Assistance Publique Hopitaux De Paris· Source

• Recruiting

  Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients

  NCT06918002· Phase 3· Intergroupe Francophone du Myelome· Source

• Active, not recruiting

  A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight

  NCT06962280· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Clinical Evaluation of the Medtronic Implantable Insulin Pump System (MIIPS 2020) in Adult Subjects With Type 1 Diabetes (CIP347)

  NCT06739811· Medtronic MiniMed, Inc.· Source

  Contact: Sylvia Franc

• Active, not recruiting

  Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)

  NCT06331312· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

  NCT06383390· Phase 3· Eli Lilly and Company· Source

• Recruiting

  EWALL-PH OBSERVARTORY 2022

  NCT07684131· Versailles Hospital· Source

  Contact: Stephanie Haiat, MD

• Active, not recruiting

  Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)

  NCT06111586· Phase 2· Sanofi· Source

• Active, not recruiting

  Combination of PRP and XLHA Prepared With RegenMatrix Medical Device To Treat Moderate to Severe Knee Osteoarthritis

  NCT05727371· RegenLab France SAS· Source

• Recruiting

  Tranexamic acid for hyperacute spontaneous IntraCerebral Haemorrhage (TICH-3)

  2022-500587-35-01· Phase 3· University Of Nottingham· Source

• Recruiting

  CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics

  NCT05260528· Phase 2· Centre Hospitalier Universitaire de Nice· Source

• Recruiting

  Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia

  NCT05338190· Phase 3· Assistance Publique - Hôpitaux de Paris· Source

• Active, not recruiting

  A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

  NCT05556512· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)

  NCT04777916· Acute Leukemia French Association· Source

  Contact: Stéphanie HAIAT, MD

• Active, not recruiting

  Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older

  NCT04974216· Phase 2· The Lymphoma Academic Research Organisation· Source

• Active, not recruiting

  MInimal Residual Disease Adapted Strategy

  NCT04934475· Phase 3· Intergroupe Francophone du Myelome· Source

• Active, not recruiting

  Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).

  NCT04751877· Phase 3· Poitiers University Hospital· Source

• Active, not recruiting

  Rituximab from the first episode of Minimal Change Nephrotic Syndrome for preventing relapse risk in adult patients

  NCT03970577· Phase 2· Assistance Publique Hopitaux De Paris· Source

• Recruiting

  Randomized phase 3 trial comparing FOLFOX to gemcitabine in metastatic first-line in patients with pancreatic adenocarcinoma and non-fit for FOLFIRINOX (GEMFOX)

  NCT04167007· Phase 2/3· Assistance Publique Hopitaux De Paris· Source

• Active, not recruiting

  Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendations.

  NCT04144387· Intergroupe Francophone du Myelome· Source

• Active, not recruiting

  Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

  NCT04070443· Phase 2· Centre Leon Berard· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic lymphocytic leukaemia3 recruiting
• Acute myeloid leukaemia2 recruiting
• Multiple myeloma2 recruiting
• Type 1 diabetes2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Ankylosing spondylitis1 recruiting
• Chronic kidney disease1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Colorectal cancer1 recruiting
• Head and neck cancer1 recruiting
• Heart failure1 recruiting
• High blood pressure1 recruiting
• Lupus (SLE)1 recruiting
• Pancreatic cancer1 recruiting
• Psoriasis1 recruiting
• Sickle cell disease1 recruiting
• Stroke1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Withdrawn

  Combination of High-flow Nasal Oxygen (Optiflow) and Vibrating Membrane Nebuliser (Aerogen) in the Pre-hospital Setting - Before/After Study

  NCT07791992· Centre Hospitalier Sud Francilien· Source

• Completed

  Association Between CGM Metrics in Type 2 Diabetes Pregnancy and Perinatal Morbidity

  NCT06892314· Centre Hospitalier Sud Francilien· Source

• Completed

  Long-term Observation Of Patient Engagement in Automated Insulin Delivery

  NCT06858475· Centre Hospitalier Sud Francilien· Source

• Completed

  Exome Evaluation in Patients Living With Diabetes Complicated by Charcot Neuroarthropathy.

  NCT06096935· Centre Hospitalier Sud Francilien· Source

• Completed

  Hybrid Closed Loop Insulin Pump and Bariatric Surgery in Patients With Type 1 Diabetes

  NCT06294704· Centre Hospitalier Sud Francilien· Source

• Completed

  Infectious and Non-infectious Lower Respiratory Diseases in Children With Down Syndrome Followed in Pediatric Pulmonology Consultations in Ile-de-France

  NCT06336577· Centre Hospitalier Sud Francilien· Source

• Completed

  Real-world Use of Hybrid Closed Loop in Adolescents and Young Adults 15-25 Years of Age with Type 1 Diabetes

  NCT06253351· Centre Hospitalier Sud Francilien· Source

• Completed

  Determination of a Profile of Patients with Renal Failure to Be Supported As a Priority in the Care Pathway in Order to Avoid Emergency Hospitalizations.

  NCT06041737· Centre Hospitalier Sud Francilien· Source

• Completed

  Comparison With Observational Methods and Performance Assessment From Real-life Experience of Closed-Loop Insulin Delivery Systems

  NCT05932966· Centre Hospitalier Sud Francilien· Source

• Completed

  Closed-Loop Insulin Delivery During Pregnancy (IADIABENCEINTE)

  NCT05661149· Centre Hospitalier Sud Francilien· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)

  NCT05767034· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  Early Recanalization After Intravenous Thrombolysis With Tenecteplase Versus Alteplase in Distal Vessel Occlusion Strokes

  NCT05635786· Centre Hospitalier Sud Francilien· Source

• Completed

  A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)

  NCT05564039· Phase 4· Eli Lilly and Company· Source

• Completed

  Acceptability of Hybrid Closed-loop Systems in Patients Living With Highly Unbalanced Type 1 Diabetes

  NCT05282264· Centre Hospitalier Sud Francilien· Source

• Completed

  A Research Study Looking at How the Use of NovoPen® 6 for Treatment With Tresiba® & Fiasp® Affects the Blood Sugar Level in Patients With Type 1 Diabetes as Part of Local Clinical Practice

  NCT05069545· Novo Nordisk A/S· Source

• Completed

  Multicenter Retrospective Observatory of Patients With Acute Myeloid Leukemia to Core Binding Factor

  NCT05070208· Acute Leukemia French Association· Source

• Active, not recruiting

  Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

  NCT04404283· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source

• Completed

  A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

  NCT04255433· Phase 3· Eli Lilly and Company· Source

• Completed

  Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy

  NCT03993912· Phase 3· University Hospital, Lille· Source

• Completed

  Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia

  NCT04010968· Phase 2· French Innovative Leukemia Organisation· Source

• Completed

  FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation

  NCT03584711· Phase 2· Federation Francophone de Cancerologie Digestive· Source

• Completed

  PHASE III RANDOMISED TRIAL to EVALUATE FOLFOX with or WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY for LOCALLY ADVANCED or METASTATIC OESOPHAGO-GASTRIC CARCINOMA

  NCT03006432· Phase 3· Federation Francophone de Cancerologie Digestive· Source